Autoinjector, Pen, And Prefilled Syringe Capabilities

Flexible capabilities for autoinjectors, pens, and prefilled syringes support biologic drug developers from early clinical phases through commercialization. These solutions evolve with programs as fill‑finish needs change — from vials in Phase I/II to prefilled syringes, pens, and autoinjectors in Phase II/III and beyond — offering a seamless transition across development stages.

Patient‑friendly delivery options, such as YpsoMate® and UnoPen™, illustrate the breadth of device choices available. By combining adaptable technologies with end-to-end expertise, these solutions simplify development, ensure readiness for commercial production, and provide long-term support for biologics programs from early formulation through market launch.